Dr. Stephen W. Kaldor Ph.D. serves as Independent Director of the Company. Dr. Kaldor has over 25 years of experience in the biotech and pharmaceutical industries. He currently serves as Chairman of Kinnate Biopharma, Inc., a precision oncology company he previously co-founded and led as Chief Executive Officer. He also serves as Chief Executive Officer and a director of Fount Therapeutics, LLC, and as a strategic advisor for Fronthera US Pharmaceuticals LLC, both biotechnology companies. Dr. Kaldor previously served as President and Chief Executive Officer at Quanticel Pharmaceuticals, Inc., a privately-held cancer drug discovery company, from February 2011 until its acquisition by Celgene Corporation in October 2015. Prior to that, Dr. Kaldor served as President and Chief Executive Officer of Ambrx Inc., a biotechnology company from July 2007 to June 2010. He was the President and Chief Scientific Officer at Syrrx Inc., a privately-held biotechnology company, from March 2003 until its acquisition by Takeda San Diego, Inc., the U.S. Discovery Research Center for Takeda Pharmaceuticals, in March 2005, and he continued on as President and Chief Scientific Officer at Takeda until July 2007. Previously, he served on the board of directors of Resolute Therapeutics, Inc., a biotechnology company, from October 2016 through 2017, and as a scientific advisory board member of Crown Bioscience, Inc., a translational technology company, from January 2009 until its acquisition by Japan Synthetic Rubber Corporation in 2018. Previously, Dr. Kaldor served as a director of Furiex Pharmaceuticals, Inc., a publicly-traded biotechnology company, from November 2010 until its acquisition by Forest Laboratories, Inc. in 2014 and as a director of Amira Pharmaceuticals, Inc., a privately-held pharmaceutical company, from March 2008 until its acquisition by Bristol-Myers Squibb Company in 2011. He started his career at Eli Lilly and Company in 1990 and is a chemist by training.
As the Independent Director of Crinetics Pharmaceuticals Inc, the total compensation of Stephen Kaldor at Crinetics Pharmaceuticals Inc is $231,750. There are 10 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
Stephen Kaldor is 58, he's been the Independent Director of Crinetics Pharmaceuticals Inc since 2015. There are 4 older and 10 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
Stephen's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG 2, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen, and Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: